India foresees spread of generics seizures via ACTA

The drug seizure agreement between India and the EU, intended to stop European customs officials from seizing legitimate generics on their way to Africa and Latin America by claiming patent infringement, may be for naught. And India may be facing the same issue on a larger scale in the likely soon-to-be enacted Anti-Counterfeiting Trade Agreement. ACTA still promotes an EU-style legal regime that would facilitate cross-border seizures of legitimate and lawful generic medicines that transit through any member country, says one law professor. Article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.